Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients With Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)

NCT01900431 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01900431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01900431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients With Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2013
Completion date
April 30, 2016
Enrollment
58 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

uveitis